Japan's Daiichi Sankyo closing Japan plant with 150 workers

Japan's Daiichi Sankyo, which has been reorganizing its API production as part of a larger cost-cutting initiative, says it will close a plant in Japan where it has 150 employees. In a brief release, the drugmaker said production will stop this month at its API plant in Hiratsuka and that the plant will close by September. It did not say what will happen to employees. Daiichi Sankyo, which has been struggling financially in the face of patent losses, started its manufacturing assessment in 2014, reorganizing its supply chain logistics the same year. It also sold an API plant in Akita to Tokyo-based Alfresa Pharma. Release

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.